Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 1.00 |
| ▸ | GABRB1 known ✓ | P18505 | 5/20 | 1.00 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 1.00 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 1.00 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 1.00 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 1.00 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 1.00 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 1.00 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 1.00 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propofol SCHEMBL36245 | 1.00 | GABRA1 (1.00) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL10968616 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL1033835 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL5087474 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL5036811 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL8935177 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL4088686 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL10968613 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL8026569 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 | |
| Propofol SCHEMBL28506127 | 0.97 | GABRA1 (0.94) | GABRA1GABRB1GABRB2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108164419-A | The preparation and application of the propofol prodrugs of monodisperse poly glycol monomethyl ether modification | 武汉大学 | 2018-06-15 | — | — | CN | claimed |
| US-9241886-B2 | Dye composition using a particular phenolic coupler in a medium rich in fatty substances, processes and devices | L'OREAL (FR) | 2016-01-26 | — | — | US | claimed |
| US-20140053346-A1 | DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES | L'OREAL (FR) | 2014-02-27 | — | — | US | claimed |
| WO-2023274258-A1 | HETEROATOM-SUBSTITUTED AROMATIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川大学华西医院 | 2023-01-05 | — | — | WO | disclosed |
| EP-4076384-A1 | METHOD FOR PRODUCING OIL-IN-WATER EMULSIONS | Fresenius Kabi Austria GmbH (AT) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021123117-A1 | METHOD FOR PRODUCING OIL-IN-WATER EMULSIONS | FRESENIUS KABI AUSTRIA GMBH (AT) | 2021-06-24 | — | — | WO | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-208902655-U | Concentration of propofol real time on-line monitoring device in a kind of anaesthesia patient exhaled gas | 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 | 2019-05-24 | — | — | CN | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9241886-B2 | Dye composition using a particular phenolic coupler in a medium rich in fatty substances, processes and devices | L'OREAL (FR) | 2016-01-26 | — | — | US | disclosed |
| US-20140053346-A1 | DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES | L'OREAL (FR) | 2014-02-27 | — | — | US | disclosed |
| WO-2006089120-A3 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | ABRAXIS BIOSCIENCE INC (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006089120-A2 | COMPOSITIONS, METHODS OF USE AND PREPARATION OF 2,6-DIISOPROPYL PHENOL AND ANALOGS FOR ISCHEMIC INJURY | ABRAXIS BIOSCIENCE, INC (US) | 2006-08-24 | — | — | WO | disclosed |
| EP-1436029-A2 | METHODS AND APPARATUSES FOR ASSURING QUALITY AND SAFETY OF DRUG ADMINISTRATION AND MEDICAL PRODUCTS AND KITS | Scott Laboratories, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20030074223-A1 | Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits | SCOTT LABORATORIES, INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003026558-A2 | METHODS AND APPARATUSES FOR ASSURING QUALITY AND SAFETY OF DRUG ADMINISTRATION AND MEDICAL PRODUCTS AND KITS | SCOTT LABORATORIES, INC. (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1052975-A1 | PROPOFOL COMPOSITION CONTAINING SULFITE | Sicor Inc. (US) | 2000-11-22 | — | — | EP | disclosed |
| US-6147122-A | OIL IN WATER EMULSION USED FOR INJECTION WITH ANTIMICROBIAL GROWTH AGENT; PREVENTS GROWTH OF ESCHERCHIA, CANDIDA, PSEUDOMONAS, AND STAPHYLOCOCCUS | GENSIA SINCOR INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6054421-A | MIXTURE OF LIPID, SUFACTANT AND WATER | SCIMED LIFE SYSTEMS, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| WO-1999039696-A1 | PROPOFOL COMPOSITION CONTAINING SULFITE | SICOR INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140053346-A1 | DYE COMPOSITION USING A PARTICULAR PHENOLIC COUPLER IN A MEDIUM RICH IN FATTY SUBSTANCES, PROCESSES AND DEVICES | C1R, F12, AKR1C3 | GABRA1 3203/4885GABRB1 2929/4885GABRB2 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.